Table 1 Patient, disease, and transplant characteristics
Characteristics | Donor source | Â | |||
|---|---|---|---|---|---|
Father (N = 223) | Mother (N = 47) | Sibling (N = 91) | Child (N = 29) | P | |
Patient age | Â | ||||
 Median (range), years | 12 (1–36) | 11 (4–30) | 27 (4–55) | 43 (29–54) | 0.000 |
 ≥ 20 years | 61 (27.4%) | 14 (29.8%) | 72 (79.1%) | 29 (100%) | 0.000 |
 < 20 years | 162 (72.6%) | 33 (70.2%) | 19 (20.9%) | 0 (0%) |  |
Patient gender | 0.040 | ||||
 Male | 119 (53.4%) | 23 (48.9%) | 63 (69.2%) | 18 (62.1%) |  |
 Female | 104 (46.6%) | 24 (51.1%) | 28 (30.8%) | 11 (37.9%) |  |
Donor age | Â | ||||
 Median (range), years | 41 (24–63) | 37 (20–54) | 28 (7–53) | 16 (10–28) | 0.000 |
 ≥ 40 years | 125 (56.1%) | 19 (40.4%) | 6 (6.6%) | 0 (0%) | 0.000 |
 < 40 years | 98 (43.9%) | 28 (59.6%) | 85 (93.4%) | 29 (100%) |  |
Donor gender | 0.000 | ||||
 Male | 223 (100%) | 0 (0%) | 54 (59.3%) | 19 (65.5%) |  |
 Female | 0 (0%) | 47 (100%) | 37 (40.7%) | 10 (34.5%) |  |
Donor-recipient gender | 0.000 | ||||
 Male to male | 119 (53.4%) | 0 (0%) | 40 (44.0%) | 11 (37.9%) |  |
 Female to male | 0 (0%) | 23 (48.9%) | 23 (25.3%) | 7 (24.1%) |  |
 Male to female | 104 (46.6%) | 0 (0%) | 14 (15.4%) | 8 (27.6%) |  |
 Female to female | 0 (0%) | 24 (51.1%) | 14 (15.4%) | 3 (10.3%) |  |
Months from diagnosis to transplant | Â | ||||
 Median (range), months | 12 (1–260) | 8 (1–144) | 12 (1–468) | 13 (1–264) | 0.374 |
 < 12 months | 108 (48.4%) | 28 (59.6%) | 43 (47.3%) | 11 (37.9%) | 0.301 |
 ≥ 12 months | 115 (51.6%) | 19 (40.4%) | 48 (52.7%) | 18 (62.1%) |  |
Transfusion before transplant | Â | ||||
 RBC, median (range), U | 20 (1–600) | 17 (0–180) | 20 (2–300) | 16 (2–160) | 0.724 |
 PLT, median (range), U | 13.5 (0–248) | 11.5 (0–60) | 16 (0–80) | 15 (2–120) | 0.721 |
Ferritin | Â | ||||
 Median (range), ng/ml | 1701.5 (9–20251) | 1801 (189–7434) | 1978.5 (23–10550) | 1904 (197–8467) | 0.633 |
ECOG score pre-SCT, median (range) | 0.406 | ||||
 0 | 55 (24.7%) | 7 (14.9%) | 17 (18.7%) | 6 (20.7%) |  |
 1 | 121 (54.3%) | 26 (55.3%) | 57 (62.6%) | 19 (65.5%) |  |
 ≥ 2 | 47 (21.1%) | 14 (29.8%) | 17 (18.7%) | 4 (13.8%) |  |
Previous ATG treatment | 0.211 | ||||
 Yes | 42 (18.8%) | 8 (17.0%) | 14 (15.6%) | 1 (3.4%) |  |
 No | 181 (81.2%) | 39 (83.0%) | 77 (84.6%) | 28 (96.6%) |  |
Matched HLA loci at A, B, DR | 0.032 | ||||
 3/6 | 188 (84.3%) | 29 (61.7%) | 68 (74.7%) | 23 (79.3%) |  |
 4/6 | 26 (11.7%) | 13 (27.7%) | 18 (19.8%) | 5 (17.2%) |  |
 5–6/6 | 9 (4.0%) | 5 (10.6%) | 5 (5.5%) | 1 (3.4%) |  |
Donor-recipient ABO match status | 0.326 | ||||
 Match | 124 (55.6%) | 23 (48.9%) | 46 (50.5%) | 20 (69.0%) |  |
 Minor mismatch | 47 (21.1%) | 14 (29.8%) | 15 (16.5%) | 4 (13.8%) |  |
 Major mismatch | 40 (17.9%) | 8 (17.0%) | 20 (22.0%) | 3 (10.3%) |  |
 Bidirectional mismatch | 12 (5.4%) | 2 (4.3%) | 10 (11.0%) | 2 (6.9%) |  |
Number of nucleated cells | Â | ||||
 Median (range), × 108/kg | 9.44 (5.07–25.13) | 9.18 (6.57–15.29) | 9.93 (4.06–18.11) | 9.88 (5.82–16.86) | 0.628 |
Number of CD34-positive cells | Â | ||||
 Median (range), × 106/kg | 3.12 (0.14–22.47) | 2.52 (0.67–10.31) | 3.26 (0.57–11.48) | 3.48 (0.84–8.72) | 0.045 |